LMR Partners’s Avita Medical RCEL Stock Holding History

LMR Partners’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,557	Closed	-$217K	–	1072
2023 Q1	$217K	Buy	+15,557	New	+$166K	﹤0.01%	850
2021 Q2	–	Sell	-14,131	Closed	-$280K	–	1288
2021 Q1	$280K	Buy	+14,131	New	+$329K	0.01%	744

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

LMR Partners's RCEL Position: Q2 2023 in Review

LMR Partners sold out of Avita Medical (RCEL) in Q2 2023, closing a stake of 15,557 shares — an estimated $217K sold.

LMR Partners first reported a position in RCEL in Q1 2021 and held it in 2 quarters. The position peaked at $280K in Q1 2021. 80 funds tracked by Wall St. Rank hold RCEL as of Q2 2023.

LMR Partners reported no remaining Avita Medical position as of Q2 2023 after selling out during the quarter.
LMR Partners sold 15,557 Avita Medical shares in Q2 2023, an estimated $217K.
LMR Partners first reported a position in Avita Medical in Q1 2021 and held it in 2 quarters.
LMR Partners's Avita Medical position peaked at $280K in Q1 2021.
80 funds tracked by Wall St. Rank held Avita Medical as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.